AI Insight
Several biotechnology startup companies are developing and testing CRISPR-based therapeutic approaches that target epigenetic markers rather than directly editing DNA sequences. These experimental treatments are being evaluated for a range of conditions including high cholesterol levels and rare muscular disorders. The approach represents a shift toward modifying gene expression patterns without permanently altering the underlying genetic code.
Why it matters
Epigenetic editing could offer a safer alternative to traditional gene editing by making reversible changes to how genes are expressed rather than permanent DNA modifications. This approach may expand treatment options for diseases where controlling gene activity, rather than correcting mutations, is therapeutically beneficial.
Understand the Science
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder
Source: Gene-editing startups are using CRISPR to treat diseases